XTL Biopharmaceuticals Ltd Annual General Meeting Statement
02 November 2006 - 6:43PM
PR Newswire (US)
NEW YORK, November 2 /PRNewswire-FirstCall/ -- XTL
Biopharmaceuticals Ltd. (NASDAQ:XTLB)(LSE:XTL)(TASE:XTL) announced
that at its adjourned Annual General Meeting held yesterday, all
the resolutions proposed to the shareholders were approved. About
XTL Biopharmaceuticals Ltd. XTL Biopharmaceuticals Ltd. ("XTL") is
engaged in the acquisition, development and commercialization of
therapeutics for the treatment of infectious diseases, with a focus
on hepatitis C. XTL is developing XTL-2125 - a small molecule,
non-nucleoside inhibitor of the hepatitis C virus polymerase.
XTL-2125 is currently in a Phase 1 clinical trial in patients with
chronic hepatitis C. XTL is also developing XTL-6865 - a
combination of two monoclonal antibodies against the hepatitis C
virus - presently in Phase 1 clinical trials in patients with
chronic hepatitis C. XTL's hepatitis C pipeline also includes
several families of pre-clinical hepatitis C small molecule
inhibitors. XTL also has an active in-licensing and acquisition
program designed to identify and acquire additional drug
candidates. XTL is publicly traded on the NASDAQ, London, and
Tel-Aviv Stock Exchanges (NASDAQ: XTLB)(LSE:XTL)(TASE:XTL).
Contact: Ron Bentsur, Chief Executive Officer Tel: +1-212-531-5960
DATASOURCE: XTL Biopharmaceuticals Ltd CONTACT: Contact: Ron
Bentsur, Chief Executive Officer, Tel: +1-212-531-5960
Copyright
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jun 2024 to Jul 2024
XTL Biopharmaceuticals (NASDAQ:XTLB)
Historical Stock Chart
From Jul 2023 to Jul 2024